As of 2025-05-21, the Intrinsic Value of Eris Lifesciences Ltd (ERIS.NS) is 337.02 INR. This ERIS.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,470.20 INR, the upside of Eris Lifesciences Ltd is -77.10%.
The range of the Intrinsic Value is 240.21 - 499.23 INR
Based on its market price of 1,470.20 INR and our intrinsic valuation, Eris Lifesciences Ltd (ERIS.NS) is overvalued by 77.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 240.21 - 499.23 | 337.02 | -77.1% |
| DCF (Growth 10y) | 415.79 - 777.83 | 552.33 | -62.4% |
| DCF (EBITDA 5y) | 1,257.44 - 1,997.93 | 1,581.03 | 7.5% |
| DCF (EBITDA 10y) | 1,218.16 - 2,170.66 | 1,618.02 | 10.1% |
| Fair Value | 158.47 - 158.47 | 158.47 | -89.22% |
| P/E | 726.49 - 1,395.40 | 1,021.34 | -30.5% |
| EV/EBITDA | 973.59 - 1,409.90 | 1,237.38 | -15.8% |
| EPV | (31.43) - 14.28 | (8.58) | -100.6% |
| DDM - Stable | 121.70 - 226.17 | 173.94 | -88.2% |
| DDM - Multi | 366.73 - 527.69 | 432.61 | -70.6% |
| Market Cap (mil) | 200,226.53 |
| Beta | 0.87 |
| Outstanding shares (mil) | 136.19 |
| Enterprise Value (mil) | 226,074.64 |
| Market risk premium | 8.31% |
| Cost of Equity | 15.77% |
| Cost of Debt | 16.88% |
| WACC | 15.72% |